Search

Your search keyword '"Jacques, Cadranel"' showing total 753 results

Search Constraints

Start Over You searched for: Author "Jacques, Cadranel" Remove constraint Author: "Jacques, Cadranel"
753 results on '"Jacques, Cadranel"'

Search Results

1. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

2. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trialsResearch in context

3. Fully automated radiolabeling of [68Ga]Ga-EMP100 targeting c-MET for PET-CT clinical imaging

4. International survey among hepatologists and pulmonologists on the hepatic hydrothorax: plea for recommendations

5. Enhancing antifungal treatment for chronic cavitary pulmonary aspergillosis through the addition of endobronchial valve therapy

6. Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports

7. Identification of bronchoalveolar and blood immune-inflammatory biomarker signature associated with poor 28-day outcome in critically ill COVID-19 patients

9. Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells

10. Impact of COVID-19 and lockdowns on pulmonary embolism in hospitalized patients in France: a nationwide study

11. A Case of Pulmonary Adenocarcinoma Presenting with Diffuse Cystic Lesions

12. Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges

13. No evidence for a pathogen associated with pulmonary MALT lymphoma: a metagenomics investigation

14. Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group

15. Severe diffuse alveolar hemorrhage related to autoimmune disease: a multicenter study

17. Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy

18. Lung cancer is also a hereditary disease

19. Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer

20. Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer

21. Low-Coverage Whole Genome Sequencing of Cell-Free DNA From Immunosuppressed Cancer Patients Enables Tumor Fraction Determination and Reveals Relevant Copy Number Alterations

22. Gender Differences in Idiopathic Pulmonary Fibrosis: Are Men and Women Equal?

23. Pyogenic lung abscess in an infectious disease unit: a 20-year retrospective study

24. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP)

25. The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus

26. Randomised trial of first-line bronchial artery embolisation for non-severe haemoptysis of mild abundance

27. Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer

29. Rituximab for auto-immune alveolar proteinosis, a real life cohort study

30. Influence of the SARS-CoV-2 outbreak on management and prognosis of new lung cancer cases, a retrospective multicentre real-life cohort study

31. Allergic bronchopulmonary aspergillosis: A multidisciplinary review

32. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis

33. Plain language summary of publication: new information for the potential role of afatinib in treating people with NRG1 gene fusion-positive cancer

34. The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism

36. Prognostic Factors in Anti-glomerular Basement Membrane Disease: A Multicenter Study of 119 Patients

37. Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRASG12C-mutant lung cancer

38. Legends to supplementary figures and tables from RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

39. Supplementary Figure S4 from RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

40. Data from First-Line Afatinib plus Cetuximab for EGFR-Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study

41. Supplemental Methods from RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

42. Supplementary Tables from First-Line Afatinib plus Cetuximab for EGFR-Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study

43. Supplementary Table S2 from RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

44. Data from RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

45. Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial

46. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

47. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial

48. Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre study

49. Germline Mutations of Telomere-Related Genes are a Major Risk Factor for Liver Disease: A Multicentric Transversal Study

50. Integrative Medicine in Interventional Oncology: A Virtuous Alliance

Catalog

Books, media, physical & digital resources